https://www.selleckchem.com/pr....oducts/bay-2402234.h
d in pivotal trials. The significant association found betweena decreased lymphocyte count over the first 6 months of treatment andthe development of severe lymphopenia by the end of the study suggestsa connection between both variables, which could be instrumental inbeing able to predict and even prevent the occurrence of such lymphopenias. The adverse events observed in the present study are in line with those reported in previous analyses. Lymphopenia was the most common adverse event. The persistence of the medication was simila
Like
Comment
Share
